$1.69
15.75%
Nasdaq, Apr 21, 08:19 pm CET
ISIN
US03589W1027
Symbol
ANNX
Sector
Industry

Annexon Inc Stock price

$1.46
-1.29 46.91% 1M
-6.17 80.87% 6M
-3.67 71.54% YTD
-3.13 68.16% 1Y
-0.65 30.81% 3Y
-16.30 91.78% 5Y
-16.30 91.78% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.03 2.10%
ISIN
US03589W1027
Symbol
ANNX
Sector
Industry

Key metrics

Market capitalization $160.18m
Enterprise Value $-122.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.04
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-154.07m
Free Cash Flow (TTM) Free Cash Flow $-118.02m
Cash position $312.02m
EPS (TTM) EPS $-1.01
P/E forward negative
Short interest 8.93%
Show more

Is Annexon Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Annexon Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Annexon Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Annexon Inc forecast:

Buy
100%

Financial data from Annexon Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 3.45 3.45
6% 6%
-
-3.45 -3.45
6% 6%
-
- Selling and Administrative Expenses 28 28
18% 18%
-
- Research and Development Expense 119 119
5% 5%
-
-151 -151
7% 7%
-
- Depreciation and Amortization 3.45 3.45
6% 6%
-
EBIT (Operating Income) EBIT -154 -154
7% 7%
-
Net Profit -138 -138
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Annexon Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Annexon Inc Stock News

Neutral
GlobeNewsWire
5 days ago
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 202...
Neutral
Seeking Alpha
6 days ago
Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting with the FDA in H1 2025. The company has $312 million in cash, enough to fund operations into H2 2026, reducing the need for imminent fundraising. Annexon is also developing ANX007 for Geographic Atrophy, with key milestones including enrollment...
Neutral
GlobeNewsWire
13 days ago
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
More Annexon Inc News

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

Head office United States
CEO Douglas Love
Employees 100
Founded 2011
Website www.annexonbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today